Of interest: California only, not yet recruiting (May 2023)
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum-Resistant Ovarian Cancer

This is a study listed on ClinicalTrials.gov. The estimated start date is May 2023. The primary completion date is 2025. 

As you can see, for those of us in the platinum-resistant, BRCA-negative, cohort, there is very little research to inform our decision of whether or not to try Niraparib (Zejula) if it is offered to us. I did try Zejula as a maintenance drug immediately following my second successful round of platinum-based chemo. Unfortunately, the drug did not work for me and my cancer recurred within six months, resulting in the platinum-resistant diagnosis. I personally, did not have any severe reaction to the drug, just fatigue, which seems to be the norm for most of us receiving any type of cancer treatment. I have also heard of a few women who have had success with the drug for extended periods of time, with very few/mild side effects.

This is a personal decision after weighing the pros and cons for yourself. Remember that each of us is unique - different types of ovarian cancer, different types of markers, different stages of the disease, etc. And, we all respond differently to the various treatments available. Researching for yourself, followed by a discussion with a medical oncologist would be very beneficial in helping inform your decision. 


Caveat: I did not read all articles. I wanted to update this thread because there is new information and this drug has a few other discussions ongoing. 

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer (OPAL)

I was just looking at research in my previous post. I did a quick check for current trials (Ontario) and came up with the two above.